First Author: S.Ozdogan Erkul TURKEY
Co Author(s): O. Ayranci Osmanbasoglu K. Eltutar S. Baz H. Aral
Back to previous
Since D-Dimer is a sensitive biomarker for thromboembolic events and C-reactive protein (CRP) is a sensitive biomarker for inflammation, we evaluated serum D-Dimer and CRP levels to assess the possible risks in patients with exudative age related macular degeneration (AMD) according to body-mass index (BMI) and waist circumference (WC) after single intravitreal anti-VEGF injection.
Patients who had intravitreal ranibizumab or aflibercept injections in Istanbul Training and Research Hospital Retina department due to exudative AMD were recruited to the study.
Thirtythree patients were enrolled for this study. Serum D-dimer and CRP levels were measured in patients with exudative AMD before either ranibizumab or aflibercept intravitreal injection and first day thereafter. Weight, height and waist circumference of the patients were noted. Sixteen eyes (48.5%) received aflibercept and 17 eyes (51,5%) received ranibizumab injection. Nine patients (27,3%) had BMI over than 30 and 22 patients (66%) had high waist circumference.
There were no significant changes in D-Dimer and CRP levels after either ranibizumab or aflibercept intravitreal injection in whole group of patients. (p=0,74, p=0.83) In subgroup analysis also there was no difference between ranibizumab and aflibercept. Also no statistical significant difference was noted when high BMI and WC were considered.
Serum D-dimer and CRP levels were not changed after injection with either ranibizumab or aflibercept. There was also no difference when high BMI and WC were taken into account.